Comparing Semaglutide Administered Subcutaneously Once Daily to Semaglutide Administered Subcutaneously Once Weekly

Sponsor
Novo Nordisk A/S
Study ID
NCT02557620
Phase
PHASE1
Status
Completed

Conditions

  • Diabetes
  • Healthy

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • semaglutide — DRUG
    Administered subcutaneously (s.c., under the skin)once daily or once weekly.
  • placebo — DRUG
    Administered subcutaneously (s.c., under the skin)once daily or once weekly.

Study Details

This trial is conducted in Europe. The aim of this trial is to compare the steady-state exposure of semaglutide administered subcutaneously once daily to semaglutide administered subcutaneously once weekly in healthy subjects.

Key Dates

Start date
Sep 30, 2015
Status verified
Jan 2017
Primary completion
Apr 30, 2016
Completion
Apr 30, 2016

Study Design

Enrollment
113 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: semaglutide OD + placebo semaglutide OW
  • Placebo Comparator: placebo semaglutide OW + placebo semaglutide OD
  • Experimental: semaglutide OW + placebo semaglutide OD

Primary Outcome Measure

Area under the semaglutide concentration-time curves [ Time Frame: At steady-state from 0 to168 hours after dosing on day 78 ]

Related Studies